Jacobs Levy Equity Management’s Novavax NVAX Stock Holding History

Jacobs Levy Equity Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$349K	Sell	37,027 -74,240	-67%	-$665K	﹤0.01%	869
2026 Q1	$906K	Sell	111,267 -47,746	-30%	-$433K	﹤0.01%	726
2025 Q4	$1.07M	Buy	159,013 +41,305	+35%	+$311K	﹤0.01%	668
2025 Q3	$1.02M	Sell	117,708 -10,436	-8%	-$81.2K	﹤0.01%	713
2025 Q2	$807K	Buy	+128,144	New	+$849K	﹤0.01%	798
2019 Q1	–	Sell	-970	Closed	-$36K	–	1009
2018 Q4	$36K	Buy	+970	New	+$37.6K	﹤0.01%	957
2018 Q3	–	Sell	-44,085	Closed	-$1.18M	–	1045
2018 Q2	$1.18M	Sell	44,085 -9,526	-18%	-$322K	0.02%	626
2018 Q1	$2.25M	Sell	53,611 -25,871	-33%	-$1.04M	0.04%	452
2017 Q4	$1.97M	Buy	+79,482	New	+$1.94M	0.03%	459

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $526M AUM 46.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Jacobs Levy Equity Management's NVAX Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Novavax (NVAX) stake by 67% in Q2 2026, selling an estimated $665K and leaving 37,027 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #869.

Jacobs Levy Equity Management first reported a position in NVAX in Q4 2017 and has held it in 9 quarters since. The position peaked at $2.25M in Q1 2018. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

Jacobs Levy Equity Management held 37,027 shares of Novavax worth $349K as of Q2 2026.
Jacobs Levy Equity Management sold 74,240 Novavax shares in Q2 2026, an estimated $665K.
Novavax made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #869 holding.
Jacobs Levy Equity Management first reported a position in Novavax in Q4 2017 and has held it in 9 quarters since.
Jacobs Levy Equity Management's Novavax position peaked at $2.25M in Q1 2018.
266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.